Skip to main content
SpringerLink
Log in

Recombinant human erythropoietin is effective in cancer-related anaemia, but is it cost effective?

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fein DA, Lee WR, Hanlon AL, et al. Pretreatment of hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995; 13: 2077–83

    PubMed  CAS  Google Scholar 

  2. Frommhold H, Guttenberger R, Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Onkol 1998; 174 Suppl. 4: 31–4

    PubMed  Google Scholar 

  3. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865–74

    PubMed  CAS  Google Scholar 

  4. Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84: 1056–63

    PubMed  CAS  Google Scholar 

  5. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001 Aug 15; 93(16): 1204–14

    Article  PubMed  CAS  Google Scholar 

  6. Engert A. Recombinant human erythropoietin as an alternative to blood transfusion in cancer-related anaemia. Dis Manage Health Outcomes 2000 Nov; 8(5): 259–72

    Article  Google Scholar 

  7. Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998 Oct; 16(10): 3412–25

    PubMed  CAS  Google Scholar 

  8. Cremiux P-Y, Finkelstein SN, Berndt ER, et al. Cost effectiveness, quality-adjusted life-years and supportive care: recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 1999 Nov; 16 (5 Pt 1): 459–72

    Article  Google Scholar 

  9. Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998; 78(6): 781–87

    Article  PubMed  CAS  Google Scholar 

  10. British National Formulary. No. 41. London: The Pharmaceutical Press, 2001 Mar

  11. Österborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma — a randomised multicenter study. Blood 1996; 87(7): 2675–82

    PubMed  Google Scholar 

  12. Thatcher N, De Campos ES, Bell DR, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999; 80: 396–402

    Article  PubMed  CAS  Google Scholar 

  13. Barosi G, Marchetti M. The clinical utility of epoetin in cancer patients: a matter of perspective [editorial]. J Hematol 2000 May; 85(5): 449–50

    CAS  Google Scholar 

  14. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15: 1218–34

    PubMed  CAS  Google Scholar 

  15. Thomas ML. Anemia and quality of life in cancer patients: impact of transfusion and erythropoietin. Med Oncol 1998; 15 Suppl. 1: S13–8

    PubMed  Google Scholar 

  16. Ludwig H. Epoetin in cancer-related anaemia. Nephrol Dial Transplant 1999; 14 Suppl. 2: 85–92

    Article  PubMed  CAS  Google Scholar 

  17. Sowade B, Sowade O, Möcks J, et al. The safety of treatment with recombinanat human erythropoietin in clinical use: a review of controlled studies. Int J Mol Med 1998; 1(2): 303–14

    PubMed  CAS  Google Scholar 

  18. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human deficiency virus by screened blood in the United States. N Engl J Med 1995; 333: 1721–5

    Article  PubMed  CAS  Google Scholar 

  19. Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer [see comments]. Blood 1994; 84(4): 1056–63

    PubMed  CAS  Google Scholar 

  20. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 1995; 86(12): 4446–53

    PubMed  CAS  Google Scholar 

  21. Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related chemotherapy-induced anaemia in patients with solid tumours. Med Oncol 1998; 15 Suppl. 1: S19–S28

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Recombinant human erythropoietin is effective in cancer-related anaemia, but is it cost effective?. Drugs Ther. Perspect 17, 8–12 (2001). https://doi.org/10.2165/00042310-200117210-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117210-00003

Keywords

Search

Navigation